Blitz Health, LLC.

Milan (Italy), 11th September 2019 – Bormioli Pharma S.p.A. (“Bormioli Pharma”), a Triton Fund IV company announced today that HIL-INVENT GmbH. (“HIL-INVENT”), as a majority shareholder, and a newly incorporated German vehicle wholly-owned by Bormioli Pharma (“Remus BidCo”) entered into a binding agreement for the acquisition of R&G Beteiligungs GmbH (“R&G”). R&G is active in the business of plastic and glass primary packaging which are mainly used in the pharmaceutical industry. R&G employees approximately 270 people and operates through two plants in Schleusingen and Altenfeld (Germany). In the fiscal year 2018 R&G registered a turnover of Euro 25.6 m and an EBITDA equal to Euro 4.1 m (representing 16.0% margin). Through this acquisition Bormioli Pharma reinforces its presence in the German and Northern European markets, expands its current product range with complementary products and strengthens its manufacturing footprint and industrial competences. Closing of the transaction is planned for the fourth quarter of 2019 and is subject to the obtainment of the merger clearance by German competent authorities provided that no adverse circumstances which may materially affect R&G business and assets will occur in the meantime. The acquisition will be financed through an acquisition financing extended by certain financial institutions to Bormioli Pharma S.p.A. and through the reinvestment by HIL-INVENT into Blitz LuxCo S.à.r.l., the sole shareholder of Bormioli Pharma, becoming a minority shareholder with a stake of 5.3%. Leverage Ratio pre-synergies, calculated as of 30th June 2019, will remain at 5.1x.